Anixa Biosciences, Inc. · NASDAQ:ANIX
Anixa Biosciences — Investor Presentation (March 2026)
21 slides from Anixa Biosciences's investor presentation, Mar 11, 2026
Slide 1: NASDAQ:ANIX March 10, 2026
NASDAG:ANIX March 10, 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa Biosciences’ current
Slide 3: Presentation Outline
Presentation Outline « 3 < 6 < |. Strategy ll. Current Projects Update A. 2025 Achievements and Current Status B. 2026 Goals I. Q&A
Slide 4: Corporate Strategy
Corporate Strategy Corporate Strategy A. Maintain Low Cash Burn Cc. + Less Shareholder Dilution + Lower Capital Requirements + Clean Capital structure Partnership Based R&D + No Expensive Laboratory Facilities Utilize Laboratory Facilities of Partners + Low Headcount Full fime HC of 4 + Diversify Pr
Slide 5: Annual Cash Burn
Annual Cash Burn (in millions) $8.0 87.0 $6.0 $5.0 84, $3. 92. st $0.0 FY 2018 FY 2019 FY 2020 FY 2021 @ Annual Cash Burn Clinical FY 2022 Fy 2023 FY 2024 FY 2025 Aanixa
Slide 6: Clinical Programs & Development Partnerships
Clinical Programs & Development Partnerships THERAPEUTIC MECHANISM GEOGRAPHIC UPCOMING AREA OF ACTION even) RIGHTS MILESTONES PACES Ovarian Periodic data MOFFITT (¥) ones CART Cancer / Gliteal ree releases ; eh) Therapeutic Other Solid Phase | (enrollment TH aR Tumors based) INSTITUTE Vaccine Phase
Slide 7: CAR-T Program
CAR-T Program Ovarian Cancer Therapy Liraltagene autoleucel (Lira-cel)
Slide 8: Ovarian Cancer CAR-T Therapy
Aanixa Ovarian Cancer CAR-T Therapy CAR-T Technology has demonstrated Success in Liquid Tumors but no approvals in Solid Tumors Background 2025- Achievements = Unique CAR-T designed for a solid tumor = Treated Patients in the 3'¢ and 4" Dose Cohorts = Utilizes three unique attributes Continued to Ob
Slide 9: Dose-escalation first-in-human clinical trial in recurrent/chemoresistant ovarian cancer
Dose-escalation first-in-human clinical trial in recurrent/chemoresistant ovarian cancer + Pl:R. Wenham, MD Chair, Gynecologic Oncology Program Moffitt Cancer Center ° LP. vs. L.V.> Comparative safety and effectiveness fable 1. Dose-escalation scheme. Cohort Dose Level RON = Cyclophosphamide dose No
Slide 10: Lira-cel CAR-T Treatment: Recurrent Ovarian Cancer Patients- March 2026
Lira-cel CAR-T Treatment: Recurrent Ovarian Cancer Patients- March 2026 Dosage (CAR cells/kg) a Alive A Expired 10 418 Pn Median Life Expectancy = Months since Treatment Aanixa
Slide 11: Lira-Cel CAR-T - 2026 Goals
Lira-Cel CAR-T - 2026 Goals « 3 < 6 < + Lymphodepletion- Understand the benefit and need for lymphodepletion + Continue dose escalation- Dose Cohort 5 and 6 * Continue monitoring increase in patient survival * Scientific Presentation of results + Additional IP Prosecution and Grants + Pharma Partner
Slide 12: Vaccine Program
Vaccine Program Breast Cancer
Slide 13: Breast Cancer Vaccine
Aanixa Breast Cancer Vaccine = Vaccine uses a molecular mechanism that has = Completed Phase 1 Trial at Cleveland Clinic never been utilized = Presented Positive Results at San Antonio Breast = Designed to Cancer Symposium © Treat Breast Cancer in neo-adjuvant setting as well as adjuvant setting (Th
Slide 14: Phase 1 Trial
Phase 1 Trial Conducted by Cleveland Clinic, funded by U.S. Department of Defense (DOD) An open-label Phase 1 dose-escalation trial Cohort 1b Cohort 1c (Prevention Group) (Treatment * Healthy women w/mutations * Chosen to undergo Participants will * 24-36 Patients who have prophylactic mastectomy *
Slide 15: Positive Phase 1 Clinical Results
Positive Phase 1 Clinical Results All Major Endpoints Met © 35 patients dosed © 26 INBC patients who have undergone standard of care, ° but are at risk of recurrence (40-80% recur in 5 years)— cohort 1a 4 genetic tisk patients choosing prophylactic mastectomies— cohort 1b 5 patients with residual di
Slide 16: Phase 2 Breast Cancer Vaccine Trial
Phase 2 Breast Cancer Vaccine Trial Near Term- Therapeutic Approach Phase 2 trial in neo-adjuvant setting - before surgery + Faster evaluation of efficacy + Multiple types of Breast Cancer + Faster data, enabling earlier alliance with big Pharma Two Arms + Standard of Care + Vaccine + Standard of Ca
Slide 17: Breast Cancer Vaccine- 2026 Goals
Breast Cancer Vaccine- 2026 Goals « 3 < 6 < Manufacturing (production of vaccine, fill and finish, quality control) + FDA Report + FDA Meetings + Phase 2 Trial Protocol * Site Selection, sign-up and Training, in addition to Cleveland Clinic + Publications + Additional Presentations + Additional IP P
Slide 18: Pre-Clinical Pipeline
Pre-Clinical Pipeline Ovarian, Lung, Prostate, Colon
Slide 19: Collaboration with Cleveland Clinic and the National Cancer Institute
Collaboration with Cleveland Clinic and the National Cancer Institute Driven by current promising data from Breast Cancer Vaccine Clinical Trial Maintain our Lead in Prophylactic Cancer Vaccine Development Ovarian Prostate Development of Ad nal Cancer Vaccines = Bioinformatic analysis utilizing adva
Slide 20: @ fe} ©) Oo S Q
2 @ fe} ©) Oo S Q
Slide 21: 2026 Goals
2026 Goals Lymphodepletion- Understand the benefit and need for lymphodepletion Continue dose escalation- Dose Cohort 5 and & Continue monitoring increase in patient survival Scientific Presentation of result Additional IP Prosecution and Grants Pharma Partner Discussions Pre-clinical Programs Conti
Anixa Biosciences — Investor Presentation (March 2026) on 6ix